We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Testing Personalized Treatments in 5 Days With 3D

News   May 22, 2019 | Original story from University of Geneva (UNIGE)

 
Testing Personalized Treatments in 5 Days With 3D

Representative image of 3D model of colorectal carcinoma (HCT116 cells) exposed for 72 hours to treatment with a three-drug combination containing regorafenib, erlotinib and 5-fluorouracil. The cell-tracker stained cells correspond to cell nuclei (blue), live cells (green) and dead cells (red). © UNIGE, Molecular Pharmacology Group

 
 
 

RELATED ARTICLES

Clinical Trial Assessing Treatments for Preventing People at High Risk From Developing Multidrug-resistant TB Launches

News

A large clinical trial to assess treatments for preventing people at high risk from developing multidrug-resistant tuberculosis (MDR-TB) has begun. The study is comparing the safety and efficacy of a new MDR-TB drug, delamanid, with the decades-old TB drug isoniazid for preventing active MDR-TB disease in children, adolescents and adults at high risk who are exposed to adult household members with MDR-TB.

READ MORE

Gastric Stem Cells Fight Bacteria to Protect Themselves Against Cancer

News

Stem cells are not only key players in tissue regeneration, they are also capable of taking direct action against bacteria. By actively fighting colonizing bacteria, gastric stem cells protect themselves against damage that can lead to cancer.

READ MORE

New Hope for Aggressive Breast Cancer: Diabetes Drug Creates Treatment “Sweet Spot”

News

New research funded by Breast Cancer Now has shown that a drug commonly used to treat Type 2 diabetes could make breast cancer cells susceptible to new treatments.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cancer Research Cell Science Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE